Alzheimer’s disease

Chemo for cancer lowers dementia risk

Cancer chemotherapy lowered risk of Alzheimer’s disease and other neurocognitive disorders that disproportionately affect older people.

Imaging “biomarker” for Alzheimer’s disease progression

Changes in connectivity in the brain’s white matter may be a novel neuroimaging biomarker for assessing Alzheimer’s disease progression.

Angela Jefferson, PhD, is the founding director of the Vanderbilt Memory and Alzheimer’s Center, VUMC’s newest freestanding institutional center.

VUMC forms center focused on Alzheimer’s and related dementias

Leaders at Vanderbilt University Medical Center have announced that the Vanderbilt Memory and Alzheimer’s Center (VMAC), currently housed in the Department of Neurology, will become a freestanding institutional center.

New clue to Alzheimer’s disease

Combining studies of genetically diverse mouse populations and human data led to the identification of a gene associated with cognitive decline and brain changes in Alzheimer’s disease.

Grant supports research on abnormal brain aging

With the aid of an $18.2 million, five-year grant renewal from the National Institute on Aging, the Vanderbilt Memory and Aging Project (VMAP) will advance interdisciplinary research into abnormal brain aging and cognitive decline in older adults, with continuing emphasis on the role of blood flow changes in the heart and brain.

Study points to potential new approach to treating neurodegenerative diseases like glaucoma and Alzheimer’s disease

Researchers at Vanderbilt University Medical Center have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy.

1 2 3 4 5 7